A new analysis of hospital registry data reveals that patients who experience a brain bleed while taking multiple antiplatelet medications or stronger agents than aspirin face a significantly higher risk of dying in the hospital. The findings, presented at the American Stroke Association’s International Stroke Conference 2026, suggest that the type and number of antiplatelet drugs taken before a bleed can influence outcomes, opening avenues for tailored management strategies.
The study, led by Dr. Santosh Murthy of Weill Cornell Medicine, examined data from over 426,000 adults hospitalized for intracranial hemorrhage between 2011 and 2021, drawn from the American Heart Association’s Get With The Guidelines-Stroke Registry. Patients on anticoagulants were excluded. Among the cohort, 109,512 were on a single antiplatelet, 17,009 on dual therapy, and 300,558 on none. Researchers compared outcomes—death or discharge to hospice versus favorable discharge—adjusting for demographics, comorbidities, stroke severity, and hospital characteristics.
Results showed that patients taking aspirin alone had no increased risk of death compared to those on no antiplatelet therapy, and aspirin was associated with lower odds of an unfavorable outcome. However, those on stronger antiplatelet drugs (e.g., clopidogrel, prasugrel, ticagrelor) alone or in combination with aspirin had significantly higher in-hospital mortality. A trend toward worse overall outcomes was also noted in these groups.
“Previous research grouped all antiplatelets together,” Murthy explained. “Our study shows that not all antiplatelet medications carry the same risk after a brain bleed. This may help guide acute management, such as whether platelet transfusions could benefit specific patients.” Current guidelines do not recommend platelet transfusions for antiplatelet-associated brain bleeds unless surgery is needed, but the study suggests further research is warranted.
Dr. Jonathan Rosand, an American Stroke Association volunteer expert, emphasized that patients should not discontinue prescribed antiplatelet therapy without consulting their healthcare provider. “These medications save lives by preventing heart attacks and ischemic strokes. However, if a bleed occurs, it may be more serious. Patients should discuss the risks and benefits with their doctor,” he said.
Limitations of the study include the lack of data on bleed characteristics such as location and volume, which could influence severity. The findings are considered preliminary until published in a peer-reviewed journal.
Intracranial hemorrhage accounts for about 10% of all strokes in the U.S., according to the American Heart Association’s 2026 Heart Disease and Stroke Statistics. The study underscores the need for personalized approaches to managing antiplatelet therapy in patients at risk of bleeding.
